Abstract
It is important that the introduction of breast screening is closely monitored. The anticipated effect on breast cancer mortality will take 10 years or more fully to emerge, and will only occur if a succession of more short-term end points are met. Data from the Swedish two-county randomised trial provide targets that should be achieved, following a logical progression of compliance with the initial invitation, prevalence and stage distribution at the prevalence screen, the rate of interval cancers after the initial screen, the pick-up rate and stage distribution at later screening tests, the rate of interval cancers after later tests, the absolute rate of advanced cancer and finally the breast cancer mortality rate. For evaluation purposes, historical data on stage at diagnosis is desirable; it is suggested that tumour size is probably the most relevant variable available in most cases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Day, N., Williams, D. & Khaw, K. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 59, 954–958 (1989). https://doi.org/10.1038/bjc.1989.203
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.203
This article is cited by
-
Mammography screening is associated with more favourable breast cancer tumour characteristics and better overall survival: case-only analysis of 3739 Asian breast cancer patients
BMC Medicine (2022)
-
Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study
BMC Cancer (2020)
-
Recommendations for cancer screening would be different if we measured endpoints that are valid, reliable, specific, and important to patients
Cancer Causes & Control (2020)
-
The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review
BMC Cancer (2018)
-
Trends in the clinical stage distribution of breast cancer in Osaka, Japan
Breast Cancer (2018)